Evaluation of acute intestinal toxicity in relation to the volume of irradiated small bowel in patients treated with concurrent weekly gemcitabine and radiotherapy for locally advanced pancreatic cancer

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3755-3759

  Ito, Yoshinori ^a   Okusaka, Takuji ^a   Kagami, Yoshikazu ^a   Ueno, Hideki ^a   Ikeda, Masafumi ^a   Sumi, Minako ^a   Imai, Atsushi ^a   Fujimoto, Naoko ^a   Ikeda, Hiroshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemoradiotherapy; Gemcitabine; Intestinal toxicity; Pancreatic cancer

Indexed keywords

GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; DRUG INDUCED DISEASE; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL TOXICITY; HISTOGRAM; HUMAN; MALE; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SMALL INTESTINE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; FEMALE; HUMANS; INTESTINE, SMALL; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIOTHERAPY;

EID: 33750713641     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. The Gastrointestinal Tumor Study Group: A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. Ann Surg 189: 205-208, 1979.
2. Moertel CG, Frytak S, Hahn RG et al: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48: 1705-1710, 1981.
3. The Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80: 751-755, 1988.
4. Okada S. Non-surgical treatments of pancreatic cancer. Int J Clin Oncol 4: 257-266, 1999.
5. Burris HA 3rd, Moore MJ, Andersen J et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
6. Lawrence TS, Chang EY, Hahn TM et al: Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. Int J Radiat Oncol Bio Phys 34: 867-872, 1996.
7. Shewach DS and Lawrence TS: Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 14: 257-263, 1996.
8. van Putten JWG, Groen HJM, Smid K et al: End-joining deficiency and radiosensitization induced by gemcitabine. Cancer Res 61: 1585-1591, 2001.
9. Talamonti MS, Catalano PJ, Vaughn DJ et al: Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 18: 3384-3389, 2000.
10. Wolff RA, Evans DB, Gravel DM et al: Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7: 2246-2253, 2001.
11. McGinn CJ, Zalupski MM, Shureiqi I et al: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19: 4202-4208, 2001.
12. Poggi MM, Kroog GS, Russo A et al: Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 54: 670-676, 2002.
13. Blackstock AW, Tepper JE, Niedwiecki D et al: Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 34: 107-116, 2003.
14. Crane CH, Abbruzzese JL, Evans DB et al: Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52: 1293-1302, 2002.
15. Herbert SH, Solin LJ, Hoffman JP et al: Volumetric analysis of small bowel displacement from radiation portals with the use of a pelvic tissue expander. Int J Radiat Oncol Biol Phys 25: 885-893, 1993.
16. Gallagher MJ, Brereton HD, Rostock RA et al: A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys 12: 1565-1573, 1986.
17. Minsky BD, Conti JA, Huang Y et al: Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. J Clin Oncol 13: 1409-1416, 1995.
18. Baglan KL, Frazier RC, Yan D et al: The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 52: 176-183, 2002.
19. Okusaka T, Ito Y, Ueno H et al: Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 91: 673-677, 2004.
20. Ikeda M, Okada S, Tokuuye K et al: A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 86: 1551-1554, 2002.
21. Mason KA, Milas L, Hunter NR et al: Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 44: 1125-1135, 1999.
22. Muler JH, McGinn CJ, Normolle D et al: Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol 22: 238-243, 2004.